Overview

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Status:
Not yet recruiting

Trial end date:
2024-04-04

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the safety and efficacy of camrelizumab combined with chemotherapy in the first-line treatment of advanced in NSCLC patients.

Phase:

N/A

Details

Lead Sponsor:

Beijing Chest Hospital

Treatments:

Apatinib